Estimated rates of hospitalisation and death from non-steroidal anti-inflammatory drug (NSAID) attributable gastrointestinal disorders
| Estimated annual attributable rate of GI | |||||
|---|---|---|---|---|---|
| Population | End point | Age group (y) | Hospitalisation | Death | Ref |
| See text for calculations; death rates from UK mortality statistics are based on an assumption of 1.5 million elderly NSAID users.4 | |||||
| The VIGOR trial data show the difference in hospitalisation for gastrointestinal problems between patients taking rofecoxib and those taking naproxen. | |||||
| *40+ if using corticosteroids. | |||||
| GI, gastrointestinal; UGIB, upper gastrointestinal bleeding. | |||||
| 6 UK towns | UGIB | 60+ | 0.23% | 0.027% | Lewis69 |
| Nottingham, UK | UGIB | 60+ | 0.4% | NA | Hawkey3 |
| Tennessee Medicaid population | All GI | 60+ | 1.25% | NA | Smalley6 |
| VIGOR study population | All GI | 50+* | 0.7% | NA | Bombardier11 |